CJC-1295 (No DAC) – Growth Hormone-Releasing Hormone Analog for Endocrine Research

Category: Growth Hormone Secretagogue Peptides

SKU: CJC1295-NODAC-10MG | Form: Lyophilized Powder | Purity: ≥ 99% (HPLC Tested)

For Research Use Only – Not for Human Consumption

Product Overview

CJC-1295 (No DAC) is a synthetic analog of Growth Hormone-Releasing Hormone (GHRH) designed to promote the natural release of growth hormone (GH) from the anterior pituitary gland. Unlike CJC-1295 with DAC (Drug Affinity Complex), the no-DAC version has a shorter half-life and induces a more natural pulsatile GH release pattern. This peptide is commonly used in research exploring pituitary signaling, growth hormone regulation, and metabolic recovery. Its synergistic use with GHRP or ghrelin analogs (such as Ipamorelin) is a frequent subject of study for enhanced GH secretion.

CJC-1295 (No DAC) Research Summary

CJC-1295 (No DAC) acts by binding to GHRH receptors on pituitary somatotrophs, stimulating a cascade that releases endogenous GH. Without the DAC modification, it exhibits a shorter half-life (approximately 30 minutes), allowing for more physiologically consistent GH pulses. This property has made it particularly useful in research studying GH rhythm dynamics, muscle repair, and metabolic recovery.

Key research findings include:

• Promotes natural GH pulsatility with minimal desensitization (Endocrinology, 2005).
• Enhances lean muscle mass and tissue regeneration in GH-deficient models (J Endocrinol, 2008).
• Improves lipid metabolism and insulin sensitivity (Horm Metab Res, 2011).
• Demonstrates synergistic GH release when co-administered with GHRPs (Peptides, 2013).
• Supports recovery and repair following oxidative or metabolic stress (Front Endocrinol, 2019).

Due to its short-acting profile, CJC-1295 (No DAC) is ideal for research focusing on physiological GH pulsation, endocrine modulation, and metabolic recovery.

Applications in Research

• Growth hormone axis and pituitary signaling studies
• Endocrine and metabolic regulation research
• Muscle regeneration and repair investigations
• Synergistic GH release with GHRPs (e.g., Ipamorelin, GHRP-2)
• Aging and hormone rhythm restoration models

For Research Use Only

This peptide is intended solely for laboratory and preclinical research purposes. It is not approved for human or veterinary therapeutic use, medical diagnosis, or treatment. Researchers must comply with institutional biosafety and peptide-handling guidelines when using this compound.

References

• Teichman SL. et al. 'CJC-1295: A Long-Acting GHRH Analog Enhancing GH Secretion.' Endocrinology, 2005.
• Lapierre H. et al. 'Growth Hormone Pulsatility and Muscle Regeneration Induced by GHRH Analogs.' Journal of Endocrinology, 2008.
• Grimberg A. et al. 'Metabolic Regulation and Insulin Sensitivity Effects of GHRH Peptides.' Hormone and Metabolic Research, 2011.
• Bowers CY. et al. 'Synergistic GH Secretion with GHRH and GHRP Co-Administration.' Peptides, 2013.
• Casanueva FF. et al. 'Endocrine and Metabolic Role of Short-Acting GHRH Analogs.' Frontiers in Endocrinology, 2019.